MENU
+Compare
DNLI
Stock ticker: NASDAQ
AS OF
Jun 5, 04:59 PM (EDT)
Price
$14.22
Change
-$0.20 (-1.39%)
Capitalization
2.09B

DNLI Denali Therapeutics Forecast, Technical & Fundamental Analysis

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease... Show more

Industry: #Biotechnology
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for DNLI with price predictions
Jun 04, 2025

DNLI's Indicator enters downward trend

The Aroon Indicator for DNLI entered a downward trend on June 04, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator formed such a pattern. In of the 223 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for DNLI moved out of overbought territory on May 01, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for DNLI crossed bearishly below the 50-day moving average on May 20, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 02, 2025. You may want to consider a long position or call options on DNLI as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DNLI just turned positive on June 04, 2025. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

DNLI moved above its 50-day moving average on June 04, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DNLI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.866) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). DNLI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. DNLI's P/S Ratio (3333.333) is very high in comparison to the industry average of (265.014).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

DNLI is expected to report earnings to fall 8.64% to -71 cents per share on July 31

Denali Therapeutics DNLI Stock Earnings Reports
Q2'25
Est.
$-0.71
Q1'25
Missed
by $0.08
Q4'24
Beat
by $0.17
Q3'24
Missed
by $0.03
Q2'24
Beat
by $0.08
The last earnings report on May 06 showed earnings per share of -77 cents, missing the estimate of -69 cents. With 1.22M shares outstanding, the current market capitalization sits at 2.09B.
A.I. Advisor
published General Information

General Information

a biotechnology company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
161 Oyster Point Boulevard
Phone
+1 650 866-8548
Employees
445
Web
https://www.denalitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NSGRX24.12N/A
N/A
Northern Small Cap Core I
AFGGX18.26N/A
N/A
Yorktown Growth A
TORIX19.59N/A
N/A
Tortoise Energy Infrastructure TR Ins
OIEFX23.80N/A
N/A
JPMorgan Equity Income R2
APHQX15.03-0.04
-0.27%
Artisan Mid Cap Value Institutional

DNLI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+3.52%
NRIX - DNLI
56%
Loosely correlated
+0.66%
BEAM - DNLI
55%
Loosely correlated
+1.60%
ARWR - DNLI
54%
Loosely correlated
+0.78%
RGNX - DNLI
54%
Loosely correlated
-0.49%
DAWN - DNLI
52%
Loosely correlated
-0.72%
More